Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • CCI approves IHH...

    CCI approves IHH acquisition of Fortis Healthcare, Fortis Malar Hospital

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-11-02T14:48:02+05:30  |  Updated On 2 Nov 2018 2:48 PM IST
    CCI approves IHH acquisition of Fortis Healthcare, Fortis Malar Hospital
    In July, the board of Fortis Healthcare approved an Rs 4,000-crore offer from IHH Healthcare for buying 31.1 per cent stake in it. The proposal had valued the cash-strapped firm at Rs 8,880 crore.

    New Delhi: Competition watchdog CCI has approved Malaysia-based IHH Healthcare's proposed acquisition of Fortis Healthcare and Fortis Malar Hospital.


    In August, Fortis Healthcare shareholders gave their nod for the deal.




    Competition Commission of India (CCI) has approved "acquisition of Fortis Healthcare Ltd and Fortis Malar Hospital Ltd by Northern TK Venture Pte Ltd," the regulator said in a tweet Wednesday.


    Read also: Fortis to be renamed as Gleneagles, says IHH Managing Director Tan See Leng


    In July, the board of Fortis Healthcare approved an Rs 4,000-crore offer from IHH Healthcare for buying 31.1 per cent stake in it. The proposal had valued the cash-strapped firm at Rs 8,880 crore.


    Shareholders had also approved reclassifying members of promoter/promoter group to public shareholder category and classification of Northern TK Venture Pvt Ltd as a promoter.


    Read Also: Singh brothers, 8 other entities told to repay over Rs 403 crore to Fortis Healthcare: SEBI
    AcquisitionCCICompetition Commission of IndiaFortis HealthcareFortis Malar HospitalIHH HealthcareNorthern TK VentureRs 4000 crore
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok